Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
2022 · Nature · 1,137 citations
https://doi.org/10.1038/s41586-022-04474-x
F
Federica Mescia
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
92
Papers
8.9K
Citations
24
h-index
39
i10-index
Federica Mescia is an academic researcher from Surgical Specialties (Canada). The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & COVID-19 Clinical Research Studies & Vasculitis and related conditions. The author has an h-index of 24, co-authored 79 publications.
ORCID: 0000-0002-2759-4027Papers by this author
worksSARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity
2022 · Cell Reports · 49 citations
https://doi.org/10.1016/j.celrep.2022.111220
The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult
2022 · Kidney International Reports · 24 citations
https://doi.org/10.1016/j.ekir.2022.05.024
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups
2023 · Frontiers in Immunology · 24 citations
https://doi.org/10.3389/fimmu.2023.1162171
sMR and PTX3 levels associate with COVID-19 outcome and survival but not with Long COVID
2024 · iScience · 5 citations
https://doi.org/10.1016/j.isci.2024.110162
Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN
2025 · Clinical Journal of the American Society of Nephrology · 0 citations
https://doi.org/10.2215/cjn.0000000953
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat